{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"224.9","value":"529.5"},{"groupId":"OG001","spread":"134.8","value":"311.0"},{"groupId":"OG002","spread":"168.1","value":"373.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"92"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"872.3","value":"1686.5"},{"groupId":"OG001","spread":"640.0","value":"1255.1"},{"groupId":"OG002","spread":"586.6","value":"1371.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"45"}],"units":"Participants"}],"title":"Cycle 1 Day 21"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"92"}],"units":"Participants"}],"description":"C2h is the plasma concentration of erdafitinib at 2 hours.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received single dose of erdafitinib 10 mg tablet, orally, once daily, starting from Day 1 through Day 7 and from Day 15 through Day 21 and so on, that is 7-day on and off in each subsequent 28-day cycles starting from Cycle 1. Based on serum phosphate (PO4) levels, there was an option to up-titrate erdafitinib dose to 12 mg, orally, once daily starting from Cycle 2 Day 1 until disease progression, unacceptable toxicity, or any other reason for treatment discontinuation.","id":"OG000","title":"Main Study: Regimen 1: Erdafitinib 10 Milligrams (mg)/ 12 mg"},{"description":"Participants received single dose of erdafitinib 6 mg tablet, orally, once daily, starting from Day 1 through Day 28 in each subsequent 28-day cycles starting from Cycle 1. Based on serum PO4 levels, there was an option to up-titrate erdafitinib dose to 8 mg, orally, once daily starting from Cycle 2 Day 1 until disease progression, unacceptable toxicity, or any other reason for treatment discontinuation.","id":"OG001","title":"Main Study: Regimen 2: Erdafitinib 6 mg/ 8 mg"},{"description":"Participants received single dose of erdafitinib 8 mg tablet, orally, once daily, starting from Day 1 through Day 28 in each subsequent 28-day cycles starting from Cycle 1. Based on serum PO4 levels, there was an option to up-titrate erdafitinib dose to 9 mg, orally, once daily starting from Cycle 1 Day 15 until disease progression, unacceptable toxicity, or any other reason for treatment discontinuation.","id":"OG002","title":"Main Study: Regimen 3: Erdafitinib 8 mg/ 9 mg"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic analysis set included all participants who received at least 1 dose of study drug and had at least 1 sample collected during treatment to determine the drug concentration. Here, 'N' (number of participants analyzed) signifies participants evaluable for this outcome measure. Here, 'n' (number analyzed) signifies participants evaluable for this outcome measure at specified timepoints.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Days 1 and 21: Pre-dose up to 2 hours post-dose (each cycle length=28 days)","title":"Main Study: Plasma Concentration of Erdafitinib at 2 Hours (C2h)","type":"SECONDARY","unitOfMeasure":"ng/mL"}